🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Tadeusz Robak

Copernicus Memorial Hospital

ORCID: 0000-0002-3411-6357

Also affiliated with Medical University of Lodz

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile
0.208Author DataRank

Indexed papers

5in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Development of a distributed international patient data registry for hairy cell leukemia

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2109157
Top 65%
0.208DataRank
Top 65%3 citations

Mirela Anghelina, Jasmine Neal, James S. Blachly, Puneet Mathur, Omkar Lele +38 more

Papers

Driven by 11 papers — median percentile 35. Top paper: “Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study”.

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Journal of Clinical Oncology(2020)10.1200/jco.20.00948
N/A
4.9DataRank · unranked
223 citations

Jenny Wu, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario +23 more

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Blood(2022)10.1182/blood.2021015014
N/A
3.8DataRank · unranked
153 citations

Thomas J. Kipps, Barbara Eichhorst, James D’Rozario, Carolyn Owen, Sarit Assouline +16 more

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Journal of Hematology & Oncology(2021)10.1186/s13045-020-01004-y
N/A
1.9DataRank · unranked
86 citations

Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak +14 more

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

NEJM Evidence(2022)10.1056/evidoa2200006
N/A
0.818DataRank · unranked
233 citations

Carolyn Owen, Carol Moreno, George Follows, Talha Munir, Mark-David Levin +16 more

Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases

Molecules(2009)10.3390/molecules14031183
N/A
0.628DataRank · unranked
65 citations

Anna Korycka, Ewa Lech-Maranda, Pawel Robak, Tadeusz Robak

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Leukemia(2021)10.1038/s41375-021-01257-7
N/A
0.578DataRank · unranked
46 citations

Leslie A. Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema A. Bhat, James S. Blachly +34 more

Therapy of Chronic Lymphocytic Leukaemia with Purine Nucleoside Analogues

Drugs & Aging(2005)10.2165/00002512-200522120-00002
N/A
0.520DataRank · unranked
31 citations

Tadeusz Robak

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

Journal of Clinical Medicine(2024)10.3390/jcm13030823
N/A
0.373DataRank · unranked
11 citations

Tadeusz Robak, Wojciech Biernat, Ewa Robak, Tomasz Stein

Development of a distributed international patient data registry for hairy cell leukemia

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2109157
Top 65%
0.208DataRank
Top 65%3 citations

Mirela Anghelina, Jasmine Neal, James S. Blachly, Puneet Mathur, Omkar Lele +38 more

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Blood Cancer Journal(2022)10.1038/s41408-022-00760-z
N/A
0DataRank · unranked
23 citations

Robert J. Kreitman, Enrico Tiacci, Leslie A. Andritsos, Versha Banerji, Jacqueline C. Barrientos +40 more

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Blood(2022)10.1182/blood.2022015832
N/A
0DataRank · unranked
36 citations

Pierre Fenaux, Marco Gobbi, Jiřı́ Mayer, Gail J. Roboz, Jürgen Krauter +21 more